1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB0009252882


Delayed London Stock Exchange  -  11:35 2022-07-05 am EDT
1786.60 GBX   -0.89%
09:49aGLAXOSMITHKLINE : JP Morgan reaffirms its Neutral rating
07/04Sareum Holdings Says GSK Completes Acquisition of Sierra Oncology
07/03UBS Joins Investors To Deliver $1 Billion Research Site In UK For GSK
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GSK : announces £1 billion R&D investment over ten years to get ahead of infectious diseases in lower-income countries

06/23/2022 | 06:35am EDT
  • New investment supports further innovation in malaria, tuberculosis, and HIV, with a new emphasis on Neglected Tropical Diseases and anti-microbial resistance
  • GSK Global Health R&D Hubs are progressing more than 30 potential new vaccines and medicines, targeting 13 high-burden infectious diseases
  • GSK will also maintain donations of albendazole until the elimination of lymphatic filariasis, and double production of its adjuvant for use in the RTS,S malaria vaccine
  • New commitments support GSK's ambition to positively impact the health of more than 2.5 billion people in the next ten years

GSK plc (LSE/NYSE: GSK) announced today an investment of £1bn over ten years to accelerate research and development (R&D) dedicated to infectious diseases that disproportionately impact lower-income countries.

This research will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR), which continue to have a devastating toll on the most vulnerable, accounting for more than 60% of the disease burden in many lower-income countries.

Thomas Breuer, GSK Chief Global Health Officer, speaking at the Kigali Summit on Malaria and NTDs in Rwanda, said: "I am delighted to renew our commitment to global health research for the coming decade, consistent with our purpose to unite our science, technology, and talent to get ahead of disease together and our ambition to deliver health impact at scale. Through our focus on scientific innovation in Global Health, we have delivered the first malaria vaccine, RTS,S, the first radical cure of vivax malaria, tafenoquine, and a new tuberculosis vaccine candidate. GSK now has more than 30 potential new vaccines and medicines (including pre-clinical assets) in 13 high-burden infectious diseases to accelerate, and we must work collectively with urgency to bring these potentially life-saving innovations to people that need them."

Khumbize Kandodo Chiponda, Minister of Health for Malawi, said: "We have made great progress in reducing the burden of infectious diseases, including eliminating lymphatic filariasis from Malawi. But some diseases have persisted because the vaccines and medicines to prevent and treat them don't exist or have become less effective due to growing resistance. GSK's announcement demonstrates their commitment to close the innovation gap and is a pivotal step towards removing infectious disease as a barrier to a healthier and more equal world."

Specifically, the investment of £1bn for Global Health R&D will support GSK's efforts to:

  • Deliver next-generation vaccines and medicines for malaria and tuberculosis, offering shorter, simpler, safer treatment options for patients, including R&D on long-acting injectables to protect against P. falciparum malaria
  • Through ViiV Healthcare, work in partnership towards the goal of ending HIV/AIDS by developing and enabling access to innovative treatment and prevention options for people affected by HIV
  • Reduce antibiotic resistance by advancing our industry-leading pipeline for vaccines, including first-in-class vaccines against invasive non-typhoidal salmonellosis and shigellosis
  • Catalyse external funding for R&D for high-burden infectious diseases through multi-sectoral collaborations and alliances

To deliver against these targets, GSK has formed a dedicated, non-commercial Global Health Unit for which success is measured by health impact alone. The model is designed to prioritise the prevention and treatment of infectious diseases in lower-income countries where the Company's science can impact the health of millions in disease areas with little prospect of a commercial return on investment.

The function includes dedicated Global Health innovation hubs for vaccines and pharmaceuticals, which collaborate with world-class partners to accelerate the discovery and development of new vaccines and medicines. These hubs have more than 30 potential vaccines and medicines targeting 13 high-burden infectious diseases.

In addition to the £1 billion for R&D, GSK announced further significant global health investments at the Kigali meeting. The Company reaffirmed its commitment to supply albendazole, the largest medicine donation ever made, until lymphatic filariasis and soil-transmitted helminthiasis morbidity are eliminated as public health problems everywhere. GSK also confirmed that it is doubling production of its AS01 adjuvant for use in the RTS,S malaria vaccine to help meet projected demand for the vaccine in the medium term.

Over the next decade, this work will build on the long-term commitment and investment made by GSK in global health innovation. To date, this has delivered significant new interventions, including RTS,S, the first-ever malaria vaccine (and first-ever human vaccine against a parasite), tafenoquine, the first radical cure of vivax malaria, as well as a promising tuberculosis vaccine candidate, with development for low-income countries with high-tuberculosis burdens now led by the Bill and Melinda Gates Medical Research Institute.

These investments in global health form part of GSK's ambition to positively impact the lives of more than 2.5 billion people over the next ten years.

About GSK

GSK is a science-led global healthcare company. For further information please visit www.gsk.com/about-us.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and any impacts of the COVID-19 pandemic.


GSK plc published this content on 23 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 June 2022 10:34:07 UTC.

© Publicnow 2022
All news about GSK PLC
09:49aGLAXOSMITHKLINE : JP Morgan reaffirms its Neutral rating
07/04Sareum Holdings Says GSK Completes Acquisition of Sierra Oncology
07/03UBS Joins Investors To Deliver $1 Billion Research Site In UK For GSK
07/01GSK completes acquisition of Sierra Oncology
07/01GSK Completes $1.9 Billion Purchase of Sierra Oncology
07/01GSK : completes acquisition of Sierra Oncology - Form 6-K
07/01GLAXOSMITHKLINE : Credit Suisse maintains a Sell rating
07/01Pharmaceutical companies still have the upper hand
06/30GSK PLC : Monthly statement on outstanding equity shares and voting rights
06/29Sierra Oncology Shareholders Approve Acquisition by GSK
More news
Analyst Recommendations on GSK PLC
More recommendations
Sales 2022 36 213 M 43 113 M 43 113 M
Net income 2022 5 295 M 6 304 M 6 304 M
Net Debt 2022 17 756 M 21 140 M 21 140 M
P/E ratio 2022 16,5x
Yield 2022 2,90%
Capitalization 91 218 M 110 B 109 B
EV / Sales 2022 3,01x
EV / Sales 2023 2,86x
Nbr of Employees 90 096
Free-Float 93,6%
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 1 802,60 GBX
Average target price 1 868,86 GBX
Spread / Average Target 3,68%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Hal V. Barron Executive Director & Chief Scientific Officer
Jon Ellis VP & Head-Technology Business Development
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC12.20%110 496
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ROCHE HOLDING AG-14.90%274 360
ABBVIE INC.13.59%271 782